Zobrazeno 1 - 10 of 745 pro vyhledávání: '"Eholie S"'
1
Akademický článek
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial
Autor: Reynes, J, Delaporte, E, Koulla-Shiro, S, Ndour, CT, Sawadogo, AB, Seidy, M, Le Moing, V, Calmy, A, Ciaffi, L, Gueye, NF Ngom, Girard, PM, Eholie, S, Guiard-Schmid, JB, Chaix, ML, Kouanfack, C, Tita, I, Bazin, B, Garcia, P, Izard, S, Eymard-Duvernay, S, Peeters, M, Serrano, L, Cournil, A, Mbouyap, PR, Toby, R, Manga, N, Ayangma, L, Mpoudi, M, Zoungrana, Ngole J, Diallo, M, Aghokeng, AF, Guichet, E, Bell, O, Abessolo, H Abessolo, Djoubgang, MR, Manirakiza, G, Lamarre, G, Mbarga, T, Epanda, S, Bikie, A, Nke, T, Massaha, N, Nke, E, Bikobo, D, Olinga, J, Elat, O, Diop, A, Diouf, B, Bara, N, Fall, MB Koita, Kane, C Toure, Seck, FB, Ba, S, Njantou, P, Ndyaye, A, Fao, P, Traore, R, Sanou, Y, Bado, G, Coulibaly, M, Some, E, Some, J, Kambou, A, Tapsoba, A, Sombie, D, Sanou, S, Traore, B, Flandre, P, Michon, C, Drabo, J, Simon, F, Ciaffi, Laura, Koulla-Shiro, Sinata, Sawadogo, Adrien Bruno, Ndour, Cheik Tidiane, Eymard-Duvernay, Sabrina, Mbouyap, Pretty Rosereine, Ayangma, Liliane, Zoungrana, Jacques, Gueye, Ndeye Fatou Ngom, Diallo, Mohamadou, Izard, Suzanne, Bado, Guillaume, Kane, Coumba Toure, Aghokeng, Avelin Fobang, Peeters, Martine, Girard, Pierre Marie, Le Moing, Vincent, Reynes, Jacques, Delaporte, Eric
Publikováno v: In The Lancet HIV September 2017 4(9):e384-e392
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Report
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Autor: Coelho LE; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Chazallon C; National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France., Laureillard D; Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes, France.; Research Unit 1058, Pathogenesis and Control Chronical Infections, INSERM, French Blood Center, University of Montpellier, Montpellier, France., Escada R; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., N'takpe JB; National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France.; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire., Timana I; Instituto Nacional de Saúde, Marracuene, Mozambique., Messou E; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire.; Centre de Prise en Charge de Recherche et de Formation, CePReF-Aconda-VS, Abidjan, Cote D'Ivoire.; Département de Dermatologie et d'Infectiologie, UFR des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Cote d'Ivoire., Eholie S; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire.; Département de Dermatologie et d'Infectiologie, UFR des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Cote d'Ivoire., Khosa C; Instituto Nacional de Saúde, Marracuene, Mozambique., Chau GD; Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam., Cardoso SW; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Veloso VG; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Delaugerre C; Virology department, APHP-Hôpital Saint-Louis, Paris, France.; INSERM U944, Paris, France.; Université Paris Cité, Paris, France., Molina JM; INSERM U944, Paris, France.; Université Paris Cité, Paris, France.; Infectious Diseases Department, AP-HP-Hôpital Saint-Louis Lariboisière, Paris, France., Grinsztejn B; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Marcy O; National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France., De Castro N; National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France.; Infectious Diseases Department, AP-HP-Hôpital Saint-Louis Lariboisière, Paris, France.
Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jan 22; Vol. 11 (3), pp. ofae035. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2024).
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
Autor: Barry, H, Mutua, G, Kibuuka, H, Anywaine, Z, Sirima, SB, Meda, N, Anzala, O, Eholie, S, Bétard, C, Richert, L, Lacabaratz, C, McElrath, MJ, de Rosa, S, Cohen, KW, Shukarev, G, Robinson, C, Gaddah, A, Heerwegh, D, Bockstal, V, Luhn, K, Leyssen, M, Douoguih, M, Thiébaut, R, Thiebaut, R
Publikováno v: PLoS Medicine, Vol 18, Iss 10 (2021)
PLoS Medicine, Vol 18, Iss 10, p e1003813 (2021)
Background We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. Methods and findings In this randomised,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6f3976241827ac97474f5ced9d54f966
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/?tool=EBI
Zobrazit plný text záznamu
7
Akademický článek
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
Autor: McLean C; Janssen Vaccines and Prevention BV, Leiden, the Netherlands. Electronic address: cmclean@its.jnj.com., Barry H; Centre MURAZ, Bobo-Dioulasso, Burkina Faso., Kieh M; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia., Anywaine Z; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda., Tapima Rogers B; University of Sierra Leone, Freetown, Sierra Leone., Doumbia S; University Clinical Research Center, University of Sciences, Technique and Technology of Bamako, Bamako, Mali., Sirima SB; Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso., Serry-Bangura A; University of Sierra Leone, Freetown, Sierra Leone., Habib Beavogui A; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Mafèrinyah, Guinea., Gaddah A; Janssen Research and Development, Beerse, Belgium., Katwere M; Janssen Vaccines and Prevention BV, Leiden, the Netherlands., Hendriks J; Janssen Vaccines and Prevention BV, Leiden, the Netherlands., Keshinro B; Janssen Vaccines and Prevention BV, Leiden, the Netherlands., Eholie S; Medical School, University Felix Houphouet Boigny, Abidjan, Cote d'Ivoire., Kibuuka H; Makerere University Walter Reed Project, Kampala, Uganda., Kennedy SB; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia., Anzala O; Kenya AIDS Vaccine Initiative (KAVI), University of Nairobi, Nairobi, Kenya., Samai M; University of Sierra Leone, Freetown, Sierra Leone., D'Ortenzio E; ANRS Emerging Infectious Diseases, Institut national de la santé et de la recherche médicale (Inserm), Paris, France., Leigh B; University of Sierra Leone, Freetown, Sierra Leone., Sow S; Centre pour le Développement des Vaccins, Bamako, Mali., Thiébaut R; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France., Greenwood B; London School of Hygiene and Tropical Medicine, London, UK., Watson-Jones D; London School of Hygiene and Tropical Medicine, London, UK; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania., Douoguih M; Janssen Vaccines and Prevention BV, Leiden, the Netherlands., Luhn K; Janssen Vaccines and Prevention BV, Leiden, the Netherlands., Robinson C; Janssen Vaccines and Prevention BV, Leiden, the Netherlands.
Publikováno v: EBioMedicine [EBioMedicine] 2023 May; Vol. 91, pp. 104562. Date of Electronic Publication: 2023 Apr 24.
Zobrazit plný text záznamu
8
Isoniazid Preventive Therapy Added to ART to Prevent TB: An Individual Participant Data Meta-Analysis
Autor: Ross, J, Badje, A, Rangaka, M, Walker, AS, Shapiro, A, Thomas, K, Anglaret, X, Eholie, S, Gabillard, D, Boulle, A, Maartens, G, Wilkinson, RJ, Ford, N, Golub, J, Williams, B, Barnabas, R
Background: Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality. We
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::08c08cf9aa28c91cc2ed4b73df8c9067
http://hdl.handle.net/10044/1/84799
Zobrazit plný text záznamu
9
Akademický článek
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis.
Autor: De Castro N; Bordeaux Population Health Centre, Research Institute for Sustainable Development (IRD) EMR 271, National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France.; Infectious Diseases Department, AP-HP-Hôpital Saint-Louis Lariboisière, Paris, France., Chazallon C; Bordeaux Population Health Centre, Research Institute for Sustainable Development (IRD) EMR 271, National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France., N'takpe JB; Bordeaux Population Health Centre, Research Institute for Sustainable Development (IRD) EMR 271, National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France.; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire., Timana I; Instituto Nacional de Saúde, Marracuene, Mozambique., Escada R; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Wagner S; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Messou E; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire.; Centre de Prise en Charge de Recherche et de Formation, CePReF-Aconda-VS, Abidjan, Côte-d'Ivoire., Eholie S; Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire.; Département de Dermatologie et d'Infectiologie, UFR des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Cote d'Ivoire., Bhatt N; Instituto Nacional de Saúde, Marracuene, Mozambique., Khosa C; Instituto Nacional de Saúde, Marracuene, Mozambique., Laureillard D; Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes, France.; Pathogenesis and Control of Chronic and Emerging Infections, INSERM UMR 1058, University of Montpellier, Montpellier, France., Do Chau G; Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam., Veloso VG; Instituto Nacional de Saúde, Marracuene, Mozambique., Delaugerre C; Virology Department, APHP-Hôpital Saint-Louis, Paris.; INSERM U944, Paris.; Université de Paris., Anglaret X; Bordeaux Population Health Centre, Research Institute for Sustainable Development (IRD) EMR 271, National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France., Molina JM; Infectious Diseases Department, AP-HP-Hôpital Saint-Louis Lariboisière, Paris, France.; INSERM U944, Paris.; Université de Paris., Grinsztejn B; Instituto Nacional de Saúde, Marracuene, Mozambique., Marcy O; Bordeaux Population Health Centre, Research Institute for Sustainable Development (IRD) EMR 271, National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France.
Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2022 Nov 19; Vol. 9 (12), pp. ofac628. Date of Electronic Publication: 2022 Nov 19 (Print Publication: 2022).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje